Quote:
Originally Posted by BNA/LION
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain
|
You have to have a subscription to read that. Although the title says it all, another source that I found said (IIRC) that the company projects a six month wait for a response from the FDA. Which I hope will be positive.
Me personally, I'm not selling my position, but I predict (yes kids you read it here first) that in the next few months the stock will continue to edge downwards, and one should add to your position when it gets below whatever target you may set. 18, maybe 17.50... whatever.
Assuming that the drug is approved, the stock should perform admirably.
